Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Trapping and Killing Glioblastoma

Project description

Pioneering targeted therapy to disrupt DNA repair in glioblastoma cells

Glioblastoma is a fast-growing and aggressive form of brain cancer. There are an estimated 250 000 new cases worldwide each year, of which only a small fraction of patients survive beyond five years. Standard treatment involves surgical removal of the tumour, followed by radiation and oral chemotherapy with Temozolomide (TMZ) to eradicate the cancer cells. Unfortunately, the cancer cells quickly build up therapy resistance owing to DNA repair mechanisms. This strongly suggests that targeted therapy could prove more effective. Through a multidisciplinary approach, the ERC-funded TrapKill project aims to develop a novel therapeutic trifunctionalised hydrogel that will disrupt DNA repair mechanisms in the cancer cells, thus increasing their vulnerability to radiotherapy and TMZ chemotherapy.

Objective

Glioblastoma Multiforme(GB) is an aggressive brain cancer associated with a 2% 5-year survival rate and 250,000 new diagnoses globally.Gold standard treatment includes surgical resection and radiotherapy coupled with Temozolomide(TMZ) chemotherapy that promote cancer cell death.Resistance to TMZ and radiotherapy develops rapidly due to DNA repair mechanisms, indicating that targeted disruption of them can potentiate these therapies.

TrapKill combines cancer mechanobiology, microfabrication and biomaterials engineering to develop a pioneering therapeutic trifunctionalised hydrogel,physically modified to present 3D microchannels,and chemically functionalised with GB chemoattractant CXCL-12 and TMZ.These promote durotaxis/chemotaxis-mediated GB cell infiltration,constraining cells into elongated morphologies,stressing the nucleus,disrupting DNA repair mechanisms,and rendering cells susceptible to therapies. I have shown that 3D patterned hydrogels promote GB GL261 cell infiltration,forcing cells to adopt a filamentous conformation and subjecting the cell nuclei to significant shear/tension/compressive forces.Following microchannel sequestering,preliminary data indicate that cells upregulate stress-related signalling processes and lose the protective effects of cell agglomeration.It is envisaged that TrapKill glioblastoma therapy will significantly enhance the efficacy of gold standard chemo-radio-therapy approaches.

TrapKill objectives include:

A chemoattractant-TMZ functionalised and micropatterned hydrogel to create TrapKill therapy
Analysis of microchannel dimensions on GB cell morphology,nuclear stress and cell sensitivity to TMZ/gamma radiation in vitro
Assess transcriptome changes in mechanically stressed GB cells and in DNA repair gene transcription
Pre-clinical resection-radiation murine GB model assessment

TrapKill will create a transformative GB treatment,with a combined approach to significantly revolutionise existing/next-generation GB therapies.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-ERC - HORIZON ERC Grants

See all projects funded under this funding scheme

Call for proposal

(opens in new window) ERC-2024-STG

See all projects funded under this call

Host institution

UNIVERSITY OF GALWAY
Net EU contribution
€ 1 499 938,00
Address
UNIVERSITY ROAD
H91 Galway
Ireland
Region
Ireland Northern and Western West
Activity type
Higher or Secondary Education Establishments
Links
Total cost
€ 1 499 938,00

Beneficiaries (1)